Lonza Group AG
http://www.lonza.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lonza Group AG
Coronavirus Update: BARDA Funding Rises To $955m As Moderna Expands Phase III Trial
Moderna has updated its protocol, expanding its recruitment target to 30,000 and aiming for more ethnically diverse and at-risk groups to be included.
Fosun’s IPO Plan For India’s Gland Hits Multiple Targets
With a proposed IPO, Gland Pharma’s parent company, Fosun Pharma, hopes to raise funds for its injectables business and possibly its COVID-19 vaccine. The move will also cut Chinese ownership against a backdrop of shaky relations between India and China. As investors warm up to pharma stocks, the timing seems right.
COVID-19 Vaccine Manufacturing: Moderna CEO Worries Most About Raw Materials
Moderna's Bencal and Merck Vaccine head Markels discuss the difficulties in scaling up manufacturing capacity for vaccine candidates at BIO plenary session; CEPI CEO says his organization can help facilitate pairing of vaccine development partners.
Moderna Phase III COVID-19 Vaccine Plan To Enroll 30,000 Patients
The company finalized the Phase III program based on feedback from the US FDA and plans to start the study in July. With a 100 µg dose, Moderna says it can manufacture 500 million doses a year.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Diversified
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
- Services
- Contract Manufacturing Organization
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- Algonomics NV
- Capsugel S.A.
- HansaBioMed Life Sciences OÜ
- InterHealth Nutraceuticals, Inc.
- Lonza Group Ltd.
- MODA Technology
- Micro-Macinazione S.A.
- PharmaCell B.V.